Michael J. Thirman, MD, specializes in the medical management of adults with hematologic disorders, leukemia, lymphoma, myelodysplastic syndromes, and myeloproliferative disorders. His laboratory focuses on the role of MLL fusion proteins in the development of leukemia. The overall goals of his research are to understand the mechanisms that mediate transformation of normal hematopoietic stem cells and to develop targeted therapies based on these insights. Dr. Thirman also directs clinical trials in acute myeloid leukemia and chronic lymphocytic leukemia.
An active researcher, Dr. Thirman has published more than 65 papers, reviews, and book chapters on clinical and laboratory studies in leukemia and lymphoma. He serves on the editorial board of Blood Advances, the Medical Advisory Board of the Leukemia Research Foundation, and the Board of Trustees of the Illinois chapter of the Leukemia and Lymphoma Society. He is a recipient of the Stohlman Scholar Award by the Leukemia and Lymphoma Society and was selected as a Chicago Magazine Top Cancer Doctor.
Specialties
Board Certifications
- Internal Medicine
Memberships & Medical Societies
- American Society of Hematology
Practicing Since
- 1989
Languages Spoken
- English
Medical Education
- University of Michigan Medical School
Internship
- University of Minnesota Health
Residency
- University of Minnesota
Fellowship
- University of Chicago Medicine
News & Research
View Published Papers- Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL
- Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
- A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation
- A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
- Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
- Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
- Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
- Aetna HMO (specialists only)
- Aetna POS
- Aetna PPO
- BCBS Blue Precision HMO (specialists only)
- BCBS HMO (HMOI) (specialists only)
- BCBS PPO
- Cigna HMO
- Cigna POS
- Cigna PPO
- CountyCare *see insurance page
- Aetna Better Health *see insurance page
- Medicare
- Multiplan PPO
- PHCS PPO
- United Choice Plus POS/PPO
- United Options (PPO)
- United Select (HMO & EPO) (specialists only)
- United W500 Emergent Wrap
- Aetna Medicare Advantage HMO & PPO
- BCBS Medicare Advantage HMO & PPO
- Humana Medicare Advantage Choice PPO
- Humana Medicare Advantage Gold Choice PFFS
- Humana Medicare Advantage Gold Plus HMO
- United Choice HMO (specialists only)
- University of Chicago Health Plan (UCHP)
Our list of accepted insurance providers is subject to change at any time. You should contact your insurance company to confirm UChicago Medicine participates in their network before scheduling your appointment. If your insurance company is not listed here, or if you have any other questions, please contact Managed.Care@uchospitals.edu.
Duchossois Center for Advanced Medicine (DCAM) - Hyde Park
Request an Appointment at Duchossois Center for Advanced Medicine (DCAM) - Hyde Park
To Refer a Patient
Refer a Patient